Stock comparison
Alnylam Pharmaceuticals
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Alnylam Pharmaceuticals ALNY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 79B | HALO |
| Benjamin Graham | 80D | 83A | HALO |
| Philip Fisher | 79B | 65B | ALNY |
| Peter Lynch | 81A | 53D | ALNY |
| Joel Greenblatt | 63C | 40D | ALNY |
| Charlie Munger | 75D | 80C | HALO |
| Terry Smith | 75B | 84A | HALO |
Side-by-side metrics
| Metric | ALNY | HALO |
|---|---|---|
| Market cap | $39.71B | $8.1B |
| P/E (TTM) | 66.1x | 24.0x |
| EV/EBIT | 75.5x | 10.2x |
| ROIC (TTM) | 19.66% | 23.65% |
| Gross margin | 80.89% | 81.24% |
| Net margin | 13.46% | 23.13% |
| Revenue CAGR 5y | 44.82% | 33.23% |
| EPS CAGR 5y | 38.42% | -1.98% |
| Debt / Equity | 1.2x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- EPS CAGR 5y38.42%vs -1.98%+105%
- Market cap$39.71Bvs $8.1B+80%
- Revenue CAGR 5y44.82%vs 33.23%+26%
HALO leads on
- EV/EBIT10.2xvs 75.5x+87%
- P/E (TTM)24.0xvs 66.1x+64%
- Net margin23.13%vs 13.46%+42%
- Debt / Equity1.0xvs 1.2x+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.